Over the past decade, obesity’s perception and treatment shifted toward personalized, multifactorial approaches. With 42% of American adults battling obesity, the pharmaceutical industry eyes a $100-200 billion market by 2030. Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, both GLP-1 agonists, lead the way, but challenges persist. Non-responsive patients and severe side effects highlight the need for precision in obesity medicine. This era emphasizes a tailored strategy to address the complexity of this prevalent health concern.
